RxDoctor Payments DataLook up a doctor →

Timothy Richardson, MD

Urology · Wichita, KSNPI 1508985417

Payments from drug & device makers

$5,258,591in general payments, 2019–2025

Across 1,427 payments — averaging $3685.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.1M
  • Janssen Research & Development, LLC$1.5M
  • Siemens Medical Solutions USA, Inc.$338K
  • AstraZeneca$325K
  • Sumitomo Pharma America, Inc.$257K
  • Bayer$162K
  • plus $525K from 45 others

What the payments were for

  • Consulting fees$76,25215%
  • Speaking & faculty fees$374,65376%
  • Travel & lodging$26,3555%
  • Food & beverage$15,6373%
  • Education$1720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,258,591 in reported general payments places this provider in the 95th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$947,861
Medicare patients
1,497
Services billed
25,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide365$5,289,222
XtandiEnzalutamide242$3,306,105
NubeqaDarolutamide218$2,889,683
OrgovyxRelugolix361$950,008
LynparzaOlaparib11$171,342
Abiraterone Acetate58$107,017
MyrbetriqMirabegron170$104,728
GemtesaVibegron84$48,668
EligardLeuprolide Acetate11$14,388
Tamsulosin Hcl850$8,251
Fesoterodine Fumarate ErFesoterodine Fumarate43$6,934
Methenamine Hippurate69$6,521
Solifenacin Succinate99$3,678
Silodosin33$2,440
Finasteride277$2,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$103,560$5,289,222365 claims
Astellas Pharma US IncXtandi, Myrbetriq$71,608$3,410,833412 claims
BayerNubeqa$161,684$2,889,683218 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$257,288$998,676445 claims
AstraZenecaLynparza$324,979$171,34211 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$3,291$107,01758 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 urology providers in Kansas.

Other urology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →